Get the Stockscreener App
38.13
0.94%
-0.36
Harmony Biosciences Holdings Inc stock is traded at $38.13, with a volume of 329.97K.
It is down -0.94% in the last 24 hours and up +7.23% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$38.49
Open:
$38.44
24h Volume:
329.97K
Relative Volume:
0.37
Market Cap:
$2.20B
Revenue:
$772.53M
Net Income/Loss:
$180.90M
P/E Ratio:
12.29
EPS:
3.1024
Net Cash Flow:
$258.73M
1W Performance:
+0.85%
1M Performance:
+7.23%
6M Performance:
+19.68%
1Y Performance:
+9.82%
1-Day Range:
$37.94
$38.52
1-Week Range:
$37.47
$39.60
52-Week Range:
$25.52
$40.93
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
38.13 | 2.22B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
26,279 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Paradiem LLC - MarketBeat
Exchange Traded Concepts LLC Buys 32,923 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastWeekly Market Snapshot & Rapid Profit Portfolio - earlytimes.in
Quarterly Trades: What is the fair value of Harmony Biosciences Holdings Inc stock nowTrade Risk Summary & Daily Oversold Stock Bounce Ideas - moha.gov.vn
Why Harmony Biosciences Holdings Inc. stock is popular among millennials2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Price-Driven Insight from (HRMY) for Rule-Based Strategy - Stock Traders Daily
Can Harmony Biosciences Holdings Inc. stock maintain operating marginsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Harmony’s Epilepsy Drug Cuts Seizures in Half in Key Late-Stage Study - MyChesCo
Will Harmony Biosciences Holdings Inc. stock outperform growth indexesMarket Risk Report & Community Verified Trade Alerts - DonanımHaber
Why Harmony Biosciences Holdings Inc. stock attracts high net worth investors2025 Price Targets & Daily Entry Point Alerts - DonanımHaber
Why Harmony Biosciences Holdings Inc. stock appeals to dividend seekersJuly 2025 Outlook & Verified Chart Pattern Trade Signals - DonanımHaber
Will Harmony Biosciences Holdings Inc. stock outperform value stocksBull Run & Safe Entry Momentum Tips - Улправда
Downgrade Watch: Is Harmony Biosciences Holdings Inc. stock positioned well for digital economyWatch List & Stepwise Swing Trade Plans - DonanımHaber
Dow Update: Will Harmony Biosciences Holdings Inc. stock outperform Dow Jones indexWeekly Trend Summary & Long-Term Growth Plans - Улправда
How sustainable is Harmony Biosciences Holdings Inc. stock dividend payoutEarnings Growth Summary & Trade Opportunity Analysis Reports - Улправда
Is Harmony Biosciences Holdings Inc. stock resilient to inflation2025 Winners & Losers & Community Consensus Trade Signals - Улправда
Harmony Biosciences (NASDAQ:HRMY) Trading Down 3.9% After Insider Selling - MarketBeat
Street Watch: Will Harmony Biosciences Holdings Inc. stock outperform international peersJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Aug Wrap: How sustainable is Harmony Biosciences Holdings Inc. stock dividend payoutJuly 2025 Breakouts & Technical Entry and Exit Alerts - Улправда
Will Harmony Biosciences Holdings Inc. stock outperform Dow Jones indexPortfolio Performance Summary & Accurate Intraday Trading Signals - Улправда
Harmony Biosciences (NASDAQ:HRMY) CEO Sells $1,040,172.63 in Stock - MarketBeat
Harmony Biosciences Holdings CEO Sells All Directly Owned Common Stock - TradingView — Track All Markets
Harmony Biosciences CEO reports option exercise and share sale | HRMY SEC FilingForm 4 - Stock Titan
Harmony Biosciences partners with Beacon for EEG data in sleep trials - Investing.com Nigeria
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG - Investing News Network
Harmony Biosciences partners with Beacon for EEG data in sleep trials By Investing.com - Investing.com South Africa
Beacon Biosignals announces partnership with Harmony Biosciences - marketscreener.com
Nomura Holdings Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harmony Biosciences Appoints Ron Philip to Board of Directors - MSN
Growth Value: Will Harmony Biosciences Holdings Inc stock pay special dividendsTrade Ideas & Real-Time Buy Zone Alerts - moha.gov.vn
Federated Hermes Inc. Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Shows Niche Pharma Momentum Nasdaq Today - Kalkine Media
What analysts say about Harmony Biosciences Holdings Inc stockAutomated Trading Signals & Missed Nvidia? Don’t Miss This One - earlytimes.in
Harmony Biosciences CFO Kapadia Sandip Sells 20,000 Shares - TradingView — Track All Markets
Harmony Advances Pitolisant GR After Bioequivalence Success - Sleep Review
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MSN
Harmony Biosciences (HRMY) Shares Promising Phase 3 Trial Results for EPX-100 - GuruFocus
Harmony Biosciences reports positive data for Dravet syndrome drug By Investing.com - Investing.com South Africa
Harmony Biosciences shows seizure reduction in dravet syndrome trial - StreetInsider
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
Marshall Wace LLP Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences reports positive data for Dravet syndrome drug - Investing.com
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results - MyChesCo
Arrowstreet Capital Limited Partnership Grows Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockDividend Hike & Smart Allocation Stock Reports - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data By Investing.com - Investing.com South Africa
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):